Study of Regorafenib and Sildenafil for Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumor

In brief

This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment combination: additional patients will be enrolled at the MTD until a total of 12 patients have been treated at the MTD.

Key facts

Study ID

NCT02466802

Run by

Virginia Commonwealth University

People needed

32

Starts

2015-07-01

Expected to finish

2019-01-28

Last updated by the study team

2020-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumor that has progressed during or after treatment with approved therapies or for which there is no standard effective therapy available
• Note: patients with solid tumors for which regorafenib would be considered a standard treatment are eligible as long as regorafenib has not been previously administered
• Measurable or evaluable disease by RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Absolute neutrophil count (ANC) >= 1500/mm\^3
• Platelets >= 100,000/mm\^3
• Hemoglobin > 9 g/dL (untransfused)
• Creatinine =< 1.5 x upper limit of normal (ULN) for the laboratory or calculated or actual creatinine clearance >= 60 mL/min
• Proteinuria =< grade 1 (ie, =< 1+ [30 mg/dL] using a random urine sample or < 1.0 gm using a 24-hour sample)
• Note: if urine sample indicates >= grade 2 proteinuria (ie, 2+ [100 mg/dL]), a 24-hour urine sample must be collected and tested; urine protein in the 24-hour sample must be < 1.0 gm/24 hours • Total bilirubin =< 1.5 x ULN for the laboratory
• Exception: if a patient has documented Gilbert's syndrome and a total bilirubin is > 1.5 x ULN, the total bilirubin requirement may be waived provided the direct bilirubin is within normal limits (WNL) for the laboratory
• Aspartate aminotransferase (AST) =< 2.5 x ULN for the laboratory
• Alanine aminotransferase (ALT) =< 2.5 x ULN for the laboratory
• Alkaline phosphatase =< 2.5 x ULN for the laboratory (=< 5 x ULN for patients with cancer involving the liver and/or bone)
• Non-hematologic toxicities from previous cancer therapies resolved to =< grade 1
• International normalized ratio (INR) is =< 1.5
• Activated partial thromboplastin time (aPTT) =< 1.5 x ULN for the laboratory
• Left ventricular ejection fraction (LVEF) assessed by echocardiogram within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%
• A woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 7 days prior to initiating study treatment
• A WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatment
• Ability to understand and willingness to sign the consent form written in English
• Note: the consent form must be signed prior to the conduct of any trial-specific procedure

You may not qualify if…

• Meningeal metastases or brain metastases that are symptomatic or untreated * Note: patients who are asymptomatic and have had post-treatment imaging that indicates stable brain disease are eligible; (patients with meningeal metastasis are not eligible even if stable following treatment); also, note that brain imaging is required within 8 weeks prior to initiation of study therapy
• Any investigational agent within 4 weeks prior to initiating study treatment
• Previous therapy with regorafenib
• If sorafenib was previously administered, intolerance to sorafenib
• Inability to swallow medication
• Known or suspected malabsorption condition or obstruction
• Contraindications to sildenafil including:
• Known retinitis pigmentosa
• History of priapism related to PDE5 inhibitors (eg, sildenafil, vardenafil, tadalafil)
• Presence of nonmalignant hematologic disorders, such as sickle cell disease, that may increase the risk of priapism
• Contraindication to antiangiogenic agents, including:
• Serious non-healing wound, non-healing ulcer, or bone fracture
• Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment
• Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment
• Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatment
• History of organ allograft including corneal transplant
• Any documented history of thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment
• Note: patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study
• Evidence of bleeding diathesis or coagulopathy
• Resting systolic blood pressure (BP) < 100 mmHg
• Hypertension defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg despite optimal medical management
• Active or clinically significant cardiac disease including any of the following:
• Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment
• Myocardial infarction within 6 months prior to initiating study treatment
• Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers

Where it is running

• Virginia Commonwealth University/Massey Cancer Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.